financetom
Business
financetom
/
Business
/
Fluence Energy Fiscal Q1 Loss Widens, Lowers 2025 Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Fluence Energy Fiscal Q1 Loss Widens, Lowers 2025 Outlook
Feb 10, 2025 1:49 PM

04:37 PM EST, 02/10/2025 (MT Newswires) -- Fluence Energy ( FLNC ) reported fiscal Q1 loss late Monday of $0.32 per diluted share, compared with $0.14 loss a year earlier.

Analysts polled by FactSet expected a loss of $0.19.

Revenue in the three months ended Dec. 31 was $186.8 million, down from $364.0 million a year earlier.

The company now expects fiscal 2025 revenue of $3.1 billion to $3.7 billion, compared with its previous guidance of $3.6 billion to $4.4 billion.

Analysts polled by FactSet expect $3.92 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Thyssenkrupp starts due diligence phase on marine unit deal with Carlyle
Thyssenkrupp starts due diligence phase on marine unit deal with Carlyle
Mar 19, 2024
March 19 (Reuters) - Thyssenkrupp on Tuesday said it has entered a due diligence phase on the sale of its marine unit with investment firm Carlyle. At the same time, talks are being held with the German government on the state's participation in thyssenkrupp's marine business, the industrial conglomerate added. ...
Thyssenkrupp evaluates Carlyle's bid for marine unit
Thyssenkrupp evaluates Carlyle's bid for marine unit
Mar 19, 2024
March 19 (Reuters) - Thyssenkrupp on Tuesday said it has entered a due diligence phase on the potential partial sale of its marine unit with investment firm Carlyle . With the active involvement of Carlyle, we are now taking the necessary next step and starting the phase of an open-ended assessment of the relevant business activities, Thyssenkrupp's Executive Board member...
BRIEF-Fusion Pharmaceuticals To Be Acquired By Astrazeneca, Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer
BRIEF-Fusion Pharmaceuticals To Be Acquired By Astrazeneca, Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer
Mar 19, 2024
March 19 (Reuters) - Fusion Pharmaceuticals Inc ( FUSN ) : * FUSION PHARMACEUTICALS TO BE ACQUIRED BY ASTRAZENECA, ACCELERATING DEVELOPMENT OF NEXT-GENERATION RADIOCONJUGATES TO TREAT CANCER * REPRESENTING A TOTAL TRANSACTION VALUE OF APPROXIMATELY $2.4 BILLION INCLUDING CVR * SHAREHOLDERS TO RECEIVE $21.00 PER SHARE IN CASH AT CLOSING PLUS A NON-TRANSFERRABLE CVR OF $3.00 PER SHARE * UPFRONT...
JOYY Q4 Adjusted Earnings Rise, Revenue Declines; Issues Q1 Revenue Outlook
JOYY Q4 Adjusted Earnings Rise, Revenue Declines; Issues Q1 Revenue Outlook
Mar 19, 2024
03:15 AM EDT, 03/19/2024 (MT Newswires) -- JOYY ( YY ) reported Q4 adjusted earnings late Monday of $1.01 per diluted American depositary share, up from $0.65 per ADS a year earlier. Two analysts polled by Capital IQ expected $0.64. Revenue for the quarter ended Dec. 31 was $569.8 million, down from $604.9 million a year earlier. Four analysts surveyed...
Copyright 2023-2026 - www.financetom.com All Rights Reserved